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The recruitment of circulating endothelial progenitor cells (EPCs)
might have a beneficial effect on the clinical course of several
diseases. Endothelial damage anddetachment of endothelial cells are
known to occur in infection, tissue ischemia, and sepsis. These det-
rimental effects in EPCs are unknown. Here we elucidated whether
human EPCs internalize Bartonella henselae constituting a circulating
niche of the pathogen. B. henselae invades EPCs as shown by gen-
tamicin protection assays and transmission electron microscopy
(TEM). Dil-Ac-LDL/lectin double immunostaining and fluorescence-
activated cell sorting (FACS) analysis of EPCs revealed EPC bioactivity
after infection with B. henselae. Nitric oxide (NO) and its precursor
L-arginine (L-arg) exert a plethora of beneficial effects on vascular
function and modulation of immune response. Therefore, we tested
also the hypothesis that L-arg (1–30mM)would affect the infection of
B. henselae or tumor necrosis factor (TNF) in EPCs. Our data provide
evidence that L-arg counteracts detrimental effects induced by TNF or
Bartonella infections via NO (confirmed by DETA-NO and L-NMMA
experiments) and by modulation of p38 kinase phosphorylation.
Microarray analysis indicated several genes involved in immune
response were differentially expressed in Bartonella-infected EPCs,
whereas these genes returned in steady state when cells were
exposed to sustained doses of L-arg. Thismechanismmay have broad
therapeutic applications in tissue ischemia, angiogenesis, immune
response, and sepsis.
immune response  sepsis
Bacterial toxins and cytokines initiate a series of pathogenicevents altering endothelial function, capillary leakage, and
endothelial swelling (1). Physiologically, endothelial cells (ECs) are
attached to the extracellular matrix; however, under pathologic
conditions, ECs can be detached from the vasculature appearing in
the bloodstream (2). The production of antiangiogenic factors is
another cause for the release of ECs into the circulation (3). ECs
have a low proliferative potential; thus, adequate vascular repair
requires additional support. Growing studies established that vas-
cular repair and neoangiogenesis are mediated, at least in part, by
bone marrow stem cells (BMCs) (4–6) and endothelial progenitor
cells (EPCs) (7, 8). BMCs (9) would be important targets for some
human pathogens such as Bartonella henselae, a Gram-negative,
facultative intracellular bacteria that cause a variety of human
diseases (10). Mechanisms underlying vasculoproliferations in B.
henselae infections include inhibition of EC apoptosis (11), activa-
tion of hypoxia-inducible factor 1 and vascular endothelial growth
factor (12), and release of calcium from intracellular stores (13).
Overall, Bartonella may also promote vascular tumor formation
(14).
The interaction of human pathogen bacteria with EPCs is
unknown. Indirectly, we can gain information by the evidence that
precursor hematopoietic cells were resistant to in vitro infection
with Listeria monocytogenes, Salmonella enteritica, and Yersinia
enterocolitica, but not when these cells were differentiated (15).
Interestingly, the genusBartonella can cause long-lasting intraeryth-
rocytic bacteremia and employ hematotropism (16). Moreover,
B. henselae is the cause of cat-scratch disease and the vasculopro-
liferative bacillary angiomatosis and bacillary peliosis in humans
(17). It has been proposed an essential role for NO in T lymphocyte
activation and signal transduction (18, 19). Indeed, NO acts as a
secondmessenger, activating soluble guanyl cyclase andmodulating
mitochondrial events involved in apoptosis and biogenesis in lym-
phocytes. Mechanisms for beneficial effects of L-arginine (L-arg),
the precursor of NO, in sepsis include enhanced protein metabo-
lism, improved microcirculation, and antibacterial effects (20, 21).
Here we describe that B. henselae infects human EPCs. Moreover,
L-arg modulates the EPC response induced by TNF or Bartonella
infections.
Results
Effect of L-Arginine on Human EPC Number and Viability. Human
EPCs cultured for 3 days resulted in an adherent population
consisting of 23  4% double-positive cells for 1,1-dioctadecyl-
3,3,3,3-tetramethylindocarbocyanine-labeled acetylated LDL
(Dil-Ac-LDL) uptake (red) and lectin binding (green) (Fig. 1A),
as assessed by phase contrast f luorescent microscopy (22). By
using a specific counting (22), we establish that EPC number was
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significantly ameliorated in the presence of L-arg (3–30 mM)
both under basal conditions and in the presence of TNF- (Fig.
1A). Treatment of EPCs with TNF- impairs EPC functional
activity and number (22, 23). Accordingly, when EPCs were
incubated with TNF-, the cell number consistently decreased
compared with control cells (Fig. 1B). The presence of L-arg
during treatment with TNF- prevented the TNF--induced
reduction of cell number (P  0.05 vs. TNF-).
EPCs (22) were then infected with B. henselae at different
multiplicities of infection (MOI) in the presence or absence of
L-arg. Interestingly, results indicated that EPC number and
viability were ameliorated in the presence of L-arg at the MOI
used for Bartonella infection (Fig. 1C). Indeed, infection of EPCs
with Bartonella impaired EPC functional activity and reduced
cell number, which consistently decreased compared with unin-
fected cells (P 0.05 vs. untreated cells) (Fig. 1D). Pretreatment
of EPCs with L-arg (10–30 mM) before infection significantly
prevented the Bartonella-induced reduction of cell number (P
0.05 vs. untreated cells). Infection with B. henselae was further
investigated by fluorescence and confocal microscopy. Higher
magnifications (630) indicate morphological major differences
when EPCs are infected with increasing doses of Bartonella
[supporting information (SI) Fig. S1]. These changes appear at
higher doses when EPCs are pretreated with L-arg before
infection as shown with a MOI of 500 suggesting a protective
action of L-arg on EPCs infected with B. henselae (Fig. 2).
Particularly, cell aggregates begin to appear at aMOI of 200 until
to develop a syncytium at a MOI of 500. At a 500–1,000 MOI we
observed cytoplasmatic disruption and loss of cellular mem-
brane integrity; at 1,000 MOI no cells showed Dil-AcLDL
uptake (Fig. S1)
B. henselae Adheres to and Invades Human EPCs.We investigated the
interaction of EPCs with B. henselae by transmission electron
microscopy (TEM). Isolated EPCs were infected with B. henselae
for up to 72 h and both cell morphology and bacteria internalization
were evaluated on EPCs at 3 days after infection (Fig. 3A–I). The
ultrastructural examination revealed that adhesion of B. henselae to
cells was accompanied by the formation of cytoplasmic protrusions
of cell membranes, followed by internalization of bacteria, detect-
able in vacuoles (Fig. 3 H and I). Invasion of B. henselae into EPCs
resulted in two different intracellular patterns: diffuse perinuclear
bacteria localization, similar to a distribution pattern already de-
scribed (24), and intracellular accumulation of bacteria forming the
so-called ‘‘invasomes’’ (25). Moreover, dividing intracellular bac-
teria were also frequently observed. The examination of untreated
EPCs revealed normal morphology. EPCs infected with B. henselae
at a MOI of 500 showed mitochondria disruption and expansion of
endoplasmatic reticulum. In contrast, EPCs pretreated with L-arg
before infection with B. henselae, even at a MOI of 500, presented
a reduced number of intracellular invasomes, intact cytoplasmatic
mitochondria, and a modest expansion of smooth endoplasmatic
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Fig. 1. Effects of L-arg in presence of TNF- or
B. henselae on EPCs. (A and B) Dil-Ac-LDL up-
take and lectin binding staining of EPCs by mi-
croscopy. (A) Photomicrographs of merged
double-positive Dil-Ac-LDL/Lectin cells (Magni-
fication: 100): untreated EPCs (A1), L-arg
(10mM)-treated EPCs (A2), TNF--treated EPCs
(A3), L-arg  TNF--treated cells (A4). (B) The
bar graphs show EPC number calculated as de-
scribed (22). Results are mean SD of 13 differ-
ent experiments in duplicate. *, P  0.05 vs.
untreated controls; §, P  0.05 vs. untreated
control and L-arg; °, P 0.05 vs. TNF-. (C andD)
Dil-Ac-LDL uptake and lectin binding staining of
EPCs infected with Bartonella at different MOI,
as described in Results. In C an image for each
B. henselae infection point pretreated with or
without L-arg at the indicated concentration is
shown at 100 magnification. In D the bar
graphs indicate the percentage of EPC number.
Results are representative of five different ex-
periments in duplicate. *, P  0.05 vs. L-arg
untreated.
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reticulum compared with untreated cells. These data clearly show
that B. henselae adheres to and invades human EPCs, also con-
firming the protective role of L-arg on EPCs infected with
B. henselae. Furthermore, gentamicin protection assays quantifying
the number of intracellular B. henselae revealed a dose-dependent
increase (Fig. 3L).
Flow Cytometry Analysis. EPCs were incubated with Dil-Ac-LDL
and FITC-labeled lectin from Ulex europaeus (see Materials and
Methods). As indicated by representative four-quadrant FACS
analysis of Dil-Ac-LDL/lectin double-positive EPCs with different
treatments (Fig. 4A) and the corresponding bar graphs of EPC
percent number (Fig. 4B), EPC number was significantly higher
when cells were grown in the presence of L-arg. We considered the
lymphocyte population for counting (see the inserted forward and
sideward scatter plot image to the right of Fig. 4 A and B). We also
investigated the effects of L-arg on Bartonella-infected EPCs at
different MOI by FACS analysis. A representative forward and
sideward scatter analysis for each indicated Bartonella MOI is
shown (Fig. 4C). As shown in Fig. 4C, a novel cell population
appeared in the blue area (named population 3), which essentially
represents myelomonocytic cells CD13/CD15 positive (Fig. 4C
Lower Left, similar to granulocytes). Bar graphs indicate the per-
centage of double-positive cell number (Fig. 4D) for differentMOI.
Considering the lymphocyte gate, EPC number was significantly
reduced when infected with B. henselae at different MOI, with a
protective action of L-arg (P  0.05 vs. L-arg-untreated EPCs).
Parallel experiments were carried out also in the presence of NO
donor diethylamine-NO (DETA-NO) or NG-monomethyl-L-
arginine (L-NMMA), an inhibitor of NO synthesis, which showed
the involvement of NO in such mechanism.
p38 MAP Kinase Activation and NOx Release. The effect of TNF-
and Bartonella on EPC number was investigated in relation to
p38 MAP kinase activation (22, 23). In our experimental con-
ditions, we show that increased p38 phosphorylation after treat-
ment with TNF- was counteracted by L-arg (P  0.05 vs.
untreated control cells) (Fig. S2A). Such treatment did not
influence significantly p38 after exposure to Bartonella indicat-
ing the involvement of other signaling events (Fig. S2B). Finally,
NOx (nitrate and nitrite) release increased significantly after
exposure of EPCs to L-arg in comparison to untreated cells
(4.2 0.5 vs. 2.2 0.3 M, P 0.01) whereas it decreased after
exposure to Bartonella (MOI 200, 1.6  0.3 M, P  0.05 vs.
untreated cells). Consistently, the cotreatment of Bartonella-
infected cells with L-arg restored partially NOx levels (MOI 200,
2.1  0.3 M, P  0.05 vs. Bartonella alone).
Modulation of EPC Gene Expression by Bartonella and L-Arginine.The
cRNA generated from a pool of three different mRNA extrac-
tions (n  3 in duplicate) for each condition (EPCs, both
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Fig. 2. Bartonella and L-arginine. EPCs infected with Bartonella at a MOI of
500 in the presence or absence of L-arg. (A) Representative images by immu-
nofluorescence. (B) Selected merge images were acquired by confocal micros-
copy. (Magnification: all, 630.)
Fig. 3. The bacteria internalization was evaluated by TEM and gentamicin
protection assay. Interaction of B. henselae with EPCs is shown. (A) Untreated
EPCs. (Scale bar: 3m.) (B) EPCs treated with L-arg (10 mM). (Scale bar: 3m.) (C)
EPCs after 1 h of infection with S. aureus. (Scale bar: 3 m.) (D and F) Untreated
human EPCs after 72 h of B. henselae infection with a MOI of 200 (D) and 500 (F).
(Scale bars: 3m.) (E andG) L-arg-treated EPCs after 72 h ofB. henselae infection
withaMOIof200(E)and500(G).AdherenceandinvasionofB.henselae infection
resulted in diffuse perinuclear accumulation of bacteria and large intracellular
bacterial aggregates (invasomes). Black arrows indicate the formation of mem-
brane ruffling and uptake of single bacteria by cellular protrusions (H), leading to
internalization ofB.henselae in cell vacuoles (I). (Scale bars 0.5m.) White arrows
indicate the presence of mitochondria in F and G. In EPCs pretreated with L-arg,
the mitochondria are intact (G). (L) Intracellular presence of B. henselae in EPCs
determined by gentamicin protection assay at different MOI.
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untreated and treated with L-arg, infected and uninfected) and
arrays containing 14,500 well characterized human genes (22,215
total genes comprehensive of EST sequences) were used to
measure the effects of Bartonella infection on EPCs, untreated
or pretreated with L-arg. Only genes with a threshold of at least
50 arbitrary detection units and a signal log ratio (SLR) value1
and 1, corresponding to an absolute fold change (FC) value
of 2 [FC 2(SLR)] have been included in the lists. Major changes
were observed for genes coding proteins with known biological
functions, as listed in Table 1. The presence of several genes
involved in immune response and cell death is noteworthy.
Discussion
We demonstrate that B. henselae can be effectively taken up into
EPCs in vitro. Second, the treatment with L-arg can affect the
response of EPCs to TNF- and B. henselae via NO-dependent
mechanisms. Intraerythrocytic presence of Bartonella has been
demonstrated in vitro using anti-Bartonella antibodies (26). A
potential primary niche in Bartonella infections could be repre-
sented by BMCs (9). Thus, mobilized EPCs could carry the
pathogen to other organs and, more important, to endothelium
of microcirculation. Thus, infected EPCsmay reach endothelium
where the vasculoproliferative disorders are initiated with the
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Fig. 4. Flow cytometry analysis. (A) Repre-
sentative four-quadrant FACS analysis of Dil-
Ac-LDL/lectin double-positive EPCs with dif-
ferent treatments: untreated EPCs (A1), L-arg
(10 mM)-treated EPCs (A2), TNF--treated
EPCs (A3), and L-arg  TNF--treated cells
(A4). (B) Bar graphs showing EPCs percent
number after treatments with L-arg (1–30
mM). The lymphocyte population was con-
sidered for counting as indicated by an arrow
in the inserted forward and sideward scatter
plot image on the right. (C andD) The effects
of L-arg on Bartonella-infected EPCs by FACS
analysis. Shown is FACS analysis of Dil-Ac-
LDL/lectin double-positive EPCs, both unin-
fected and infected with B. henselae at dif-
ferent MOI, as described in Results. A
representative forward and sideward scat-
ter analysis for each indicated Bartonella
MOI is shown (C). (C Lower Left) FACS anal-
ysis for CD13-PE/CD15-FITC antigens. (D)
Bar graphs indicate the means and stan-
dard deviations of the percentage of dou-
ble-positive cell number for the different
MOI and in the presence of different treat-
ments (L-arg (3–30 mM), L-arg 10 mM plus
L-NMMA, DETA-NO). The lymphocyte pop-
ulation was considered for FACS counting.
Results are representative of five different
experiments in duplicate. *, P  0.05 vs.
L-arg untreated EPCs; °,P  0.05 vs. both
respective untreated or 10 mM L-arg EPCs.
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involvement of p38 kinase-dependent and -independent path-
ways. Until now, EPCs, which differentiate into angiogenic cells,
have never been analyzed for their capacity to interact with
human pathogens. Our in vitro data provide evidence that
infection of EPCs with human pathogenic bacteria (e.g., B.
henselae) results in the presence of bacteria in such cells.
Nutrients have traditionally been viewed as a means to provide
basic calories to sustain homeostasis during sedentary style of life
and physical exercise (27). However, critically ill, surgical, and
trauma patients are in a constant dynamic state between systemic
inflammatory response and compensatory antiinflammatory re-
sponse (1–3). Results from ongoing research support the use of
specific nutrients to modulate the immune and/or metabolic re-
sponse (20, 21, 27). However, the postulate of using nutrients as
therapeutic substances rather than just as ‘‘nutritional adjuvant
support’’ would require a shift in the current belief.Among themost
common nutrients found in currently available formulas are
omega-3 fatty acids, antioxidants, nucleotides, glutamine, and L-arg.
Multiple individual reports and at least five metaanalyses using
combinations of immune-modulating nutrients have reported al-
most uniform beneficial results (20, 21, 27, 28). However, the wide
use of L-arg in septic patients is difficult. Here, we support the
adjuvant use of L-arg against the dissemination of infected EPCs in
the bloodstream. This adverse event may compromise the tissue
regeneration and neoangiogenesis afforded by EPCs. Notably, our
microarray analysis revealed that several genes involved in immune
Table 1. Modulation of EPC gene expression by Bartonella and L-arginine
Gene title
RefSeq
transcript ID
Gene ontology
(biological process)
Chromosomal
location
L-arginine
vs. EPC
Bartonella
vs. EPC
L-arginine plus
Bartonella vs. EPC
7-dehidrocoholesterol
reductase (DHCR7)
NM001360 Blood vessel development chr11q13.2 3,0 I NDE NDE
RecQ protein like 4 (RECQL4) NM004260 DNA repair chr8q24.3 2,0 I NDE NDE
Rho GDP dissociation inhibitor
alfa (ARHGDIA)
NM004309 Antiapoptosis chr17q25.3 1,1 I NDE NDE
Talin (TLN1) NM006289 Cell motility chr9p13 3,0 D NDE NDE
Programmed cell death 11
(PDCD11)
NM014976 RNA processing ch19p13.12 1,7 D NDE NDE
Hepcidin antimicrobial peptide
(HAMP)
NM021175 Response to pathogen ch19p13.12 NDE 2,7 I NDE
IL-1 receptor, type II (IL1R2) NM004633 Inflammatory and immune
response
chr2q11.2 NDE 2,5 I NDE
Wingless-type MMTV
integration site family,
member 5A (WNT5A)
NM003392 Cell–cell signaling, signal
transduction
chr3p14.3 NDE 2,4 I NDE
Solute carrier family 7 member
11 (SLCA11)
NM014331 Cationic amino acid transporter chr4q28.3 NDE 2,4 I NDE
Superoxide dismutase 2 (SOD2) NM00636 Cellular defense response chr6q2513 NDE 1,2 I NDE
IL-1 receptor, type I (IL1R1) NM000877 Inflammatory and immune
response
chr2q12.1 NDE 1,2 I NDE
Caspase 1, apoptosis-related
cysteine peptidase (IL-1,
convertase) (CASP1)
NM001223 Apoptosis chr11q23 NDE 1,2 I NDE
Chemokine (C-C motif) ligand
20 (CCL20)
NM004591 Chemotaxis, defense response
to bacteria
chr2q36.3 NDE 2,7 D NDE
Plexin C1 (PLXNC1) NM005761 Cell adhesion chr12q22 NDE 2,5 D NDE
Laminin 4 (LAMB4) NM007356 Cell communication, focal
adhesion
chr7q31.1 NDE 2,3 D NDE
IL-1 (IL1A) NM000575 Inflammatory and immune
response
chr2q14 NDE 1,3 D NDE
Vascular endothelial growth
factor B (VEGFB)
NM003377 Regulation of progression
through cell cycle
chr11q13 NDE 1,2 I 1,4 D
Upf3 regulator of nonsense
transcripts homolog A
(UPF3A)
NM023011 mRNA catabolic process chr13q34 1,1 D 1,6 I 1,2 D
Forkhead box P1 (FOXP1) NM00101250 Transcription regulator activity chr3p14.1 1,1 D 1,2 I 1,1 D
Abhydrolase domain
containing 8 (ABHD8)
NM024527 Aromatic compound
metabolism
chr19p13.11 1,1 D 3,8 I 2,6 D
Staphylococcal nuclease
domain containing 1 (SND1)
NM014390 Regulation of transription chr7q32.1 1,3 D 1,1 I 1,3 D
Kinesin family member 5c
(KIF5C)
NM004522 Microtubule-based movement chr2q23.1 1,4 D 1,4 I 1,1 D
Caspase recruitment domain
family, member 11 (CARD11)
NM032415 Positive regulation of T and B
cell proliferation
chr7p22 1,1 D 1,4 I 1,5 D
Thrombospondin, type I,
domain containing 3 (THSD3)
NM182509 Immune response, involved in
complement pathway
chr14q24.3 1,4 D 2,4 I 4,2 D
Serine/threonine kinase 4
(STK4)
NM006282 Cell morphogenesis chr20q11.2 1,1 I 1,4 D 1,6 I
Topoisomerase (DNA) I,
mitochondrial (TOP1MT)
NM052963 DNA topological change chr8q24.3 1,1 I 1,4 D 1,1 I
IL-1 (IL1B) NM000576 Inflammatory and immune
response
chr2q14 1,2 D 1,5 D 1,0 D
Results are expressed as both the signal log ratio and the direction of the change, i.e., an increase (I) or a decrease (D).
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response were differentially expressed in Bartonella-infected EPCs,
whereas these genes showed expression levels comparable to un-
infected control cells when the EPCs were pretreated with L-arg.
Recently, it was shown that the production of NO by Helicobacter
pylori-stimulated RAW 264.7 cells was dependent on the L-arg
concentration, and the ED50 for L-arg was 220 M, which is above
reported plasma L-arg levels (29). The inducible form of NO
synthase protein increased in an L-arg-dependent manner, which
resulted in the killing of H. pylori. The average baseline plasma
concentration of L-arg in healthy subjects is 60-100 M (30, 31).
This value increases until 300 M after a single oral administration
of a 10-g dose with bioavailbility of 20% and until 6.6 mM after
intravenous administration of a 30-g dose (30, 31). In peripheral
arterial disease patients, plasma L-arg concentration increased to a
value of about 4.0 mM after 30-g dose infusion (32–34). Similar
doses (about 15g) also have been administered to patients with
chronic renal failure in a randomized controlled study (35). The
administration of L-arg in sepsis is still debated. This condition is
characterized by a reduction in plasma and tissue arginine levels
compared with healthy individuals (20, 36). Thus, L-arg has been
supplied in these patients by various forms, such as immunonutri-
tion containing arginine with a range dose between 4.5 g and 18.7
g to intravenous administration of 30g (36, 37). However, a recent
study performed on a small number of animals with septic shock
(the well characterized canine model ofEscherichia coli peritonitis)
reported that parenteral L-arg, at dose above standard dietary
practices, was markedly harmful (38). Despite the fact that our in
vitro data is not a biodynamic model of L-arg bioavailability, the
dose used in the present study is not much higher than doses
reached in humans (30–37). Thus, L-arg andNOmay exertmultiple
beneficial effects affecting tissue ischemia and its regeneration,
immune response, sepsis, and angiogenesis.
Materials and Methods
EPC Isolation and Cultivation. Experiments with human EPCs were performed
in agreement with the local ethics committee, and informed consent was
provided according to the Declaration of Helsinki. EPCs were isolated from
total peripheral blood mononuclear cells as previously described (22).
Cell Treatments and NOx Release. EPCs were incubated with L-arg (1–30 mM),
TNF- (22), NO donor diethylamine-NO (DETA-NO), or the NO inhibitor NG-
monomethyl-L-arginine (L-NMMA), and infection was induced by B. henselae
strain ATCC 49882 (LGC Promochem) or Staphylococcus aureus (SI Materials and
Methods).
Dil-Ac-LDL/Lectin Staining and Cell Number Calculation. Cells were dual-stained
with Dil-Ac-LDL and lectin from U. europaeus and counted as previously
described (22) (SI Materials and Methods).
Flow Cytometry Analysis. Dual-stained cells were analyzed by flow cytometry
(22) (SI Materials and Methods).
Western Blot Analysis. EPC extracts (20–50 g per lane) were loaded onto SDS
polyacrylamide gels, blotted onto membranes, and analyzed as described (22)
(SI Materials and Methods).
Transmission ElectronMicroscopy.Ultrathin sections (80 nm) were stained with
2% uranyl acetate (Electron Microscopy Sciences) for 10 min at room temper-
ature and 2.66% lead citrate (Electron Microscopy Sciences) for 8 min at room
temperature. Grids were examined by using a Philips EM 208 S transmission
electron microscope (Philips) operating at 80 kV at magnifications between
2,500 and 60,000 (SI Materials and Methods).
RNA Extraction and Microarray Analysis. Total RNAs were extracted from
cultured EPCs, treated and untreated, using TRIzol solution (Invitrogen) ac-
cording to the manufacturer’s instructions. cRNA was used for hybridization
onto the Affymetrix Human Genome U133 2.0 probe array cartridge (SI
Materials and Methods).
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